WBI Investments LLC Lowers Stock Position in Pfizer Inc. $PFE

Key Points

• WBI Investments LLC has reduced its holdings in Pfizer Inc. by 14.4%, selling 18,593 shares, leaving them with a total of 110,208 shares valued at $2,793,000.
• Various hedge funds have made significant changes to their stakes in Pfizer, with Brighton Jones LLC increasing theirs by a dramatic 1,282.4%, acquiring 618,117 shares.
• Pfizer recently reported a quarterly EPS of $0.78, exceeding expectations, and has set its FY 2025 guidance between $2.900-3.100 EPS.

WBI Investments LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 14.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 110,208 shares of the biopharmaceutical company's stock after selling 18,593 shares during the period. WBI Investments LLC's holdings in Pfizer were worth $2,793,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Westbourne Investments Inc. bought a new stake in shares of Pfizer during the 1st quarter worth about $2,411,000. MBL Wealth LLC acquired a new position in shares of Pfizer in the 1st quarter valued at approximately $321,000. Acadian Asset Management LLC raised its position in shares of Pfizer by 11.7% in the 1st quarter. Acadian Asset Management LLC now owns 676,698 shares of the biopharmaceutical company's stock valued at $17,141,000 after buying an additional 70,847 shares in the last quarter. Geneos Wealth Management Inc. increased its position in Pfizer by 8.5% during the 1st quarter. Geneos Wealth Management Inc. now owns 59,158 shares of the biopharmaceutical company's stock worth $1,499,000 after purchasing an additional 4,614 shares in the last quarter. Finally, Bluefin Capital Management LLC acquired a new position in Pfizer during the 1st quarter worth approximately $441,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Berenberg Bank lowered their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Down 3.8%

PFE traded down $0.95 during trading on Friday, hitting $23.91. 81,158,118 shares of the company's stock were exchanged, compared to its average volume of 34,996,196. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business's 50 day moving average is $24.79 and its two-hundred day moving average is $24.30. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a market cap of $135.94 billion, a P/E ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the company posted $0.60 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer's dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.